Xofigo Dosage: Form, Strength, How It’s Given, and More

Medical note: This article is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Xofigo is a prescription radiopharmaceutical that must be prepared and administered by trained healthcare professionals in an appropriate clinical setting.

If you have been prescribed Xofigo, you are probably not looking for a casual “take two and call me in the morning” kind of medication guide. Xofigo is different. It is not a pill, capsule, cream, patch, or mystery bottle hiding behind the orange juice in the refrigerator. Xofigo is a radioactive prescription medicine used in certain people with advanced prostate cancer that has spread to the bones.

The main keyword here is Xofigo dosage, but the real topic is bigger: how the dose is calculated, what form Xofigo comes in, how often it is given, what happens during treatment, and what patients usually need to know before each injection. Because Xofigo contains radium Ra 223 dichloride, its dosing is based on body weight and radioactivity, not on milligrams like many common medicines. In other words, this is not the medication aisle at the pharmacy; this is nuclear medicine wearing a lab coat and carrying a clipboard.

Below, you will find a clear, patient-friendly guide to Xofigo form, strength, dosing schedule, administration, missed appointments, safety monitoring, side effects, and practical experiences related to treatment.

What Is Xofigo?

Xofigo is the brand name for radium Ra 223 dichloride injection. It is classified as an alpha-emitting radiopharmaceutical. That means it gives off a type of radiation called alpha particles. These particles travel only a short distance in tissue, which allows the medicine to deliver radiation near bone metastases while limiting some exposure to nearby healthy tissue.

Xofigo is approved for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. In plain English, this means prostate cancer that no longer responds well to testosterone-lowering treatment, has spread to the bones and is causing symptoms, but is not known to have spread to organs such as the liver or lungs.

How Xofigo Works in the Body

Radium behaves somewhat like calcium. Since bones use calcium, radium Ra 223 tends to go to areas of increased bone activity, including spots where prostate cancer has spread to bone. Once there, it releases alpha radiation that can damage cancer cell DNA. Think of it as a highly specialized delivery driver: it heads toward active bone areas, drops off radiation close to the target, and does not wander around asking for directions.

Xofigo Form and Strength

Xofigo comes as a clear, colorless, sterile solution for intravenous injection. It is supplied in a single-dose vial. A healthcare professional does not send it home with you, and you do not store it in your kitchen next to the coffee creamer. It is handled in a hospital, clinic, nuclear medicine department, or another authorized medical setting.

The labeled strength of Xofigo is:

• 1,100 kBq/mL at the reference date
• 30 microcurie/mL at the reference date
• 6 mL per single-dose vial
• Total radioactivity: 6,600 kBq per vial at the reference date
• Total radioactivity: 178 microcurie per vial at the reference date

The phrase “reference date” matters because radioactive medicines decay over time. The healthcare team calculates the actual volume needed using the patient’s weight, the prescribed radioactivity dose, the concentration of the product, and a decay correction factor. Patients do not need to do this math. In fact, unless you enjoy radioactive algebra, it is best left to the professionals.

Recommended Xofigo Dosage

The standard recommended Xofigo dose is:

55 kBq per kilogram of body weight, or 1.49 microcurie per kilogram of body weight, given once every 4 weeks for 6 injections.

This is the most important dosage point. Xofigo is not given every day or every week. It is typically given once a month for a total of six doses. Safety and effectiveness beyond six injections have not been established, so the usual treatment course is limited to those six planned administrations.

Example of Weight-Based Dosing

Suppose a patient weighs 80 kilograms, which is about 176 pounds. The intended radioactivity dose would be calculated as:

80 kg × 55 kBq/kg = 4,400 kBq

That number helps the nuclear medicine team determine the volume to draw from the vial after accounting for the current radioactivity concentration and decay correction. The patient does not receive “4,400 kBq” as a pill or tablet. It is prepared as an exact volume of liquid solution for slow intravenous injection.

How Xofigo Is Given

Xofigo is given as a slow intravenous injection over about 1 minute. The IV line or cannula is usually flushed with isotonic saline before and after the injection. The injection itself is brief, but the visit may take longer because of check-in, review of labs, safety procedures, and coordination with nuclear medicine staff.

Most patients receive Xofigo in a clinical setting such as a hospital outpatient department, cancer center, or nuclear medicine unit. It should be received, stored, prepared, administered, and disposed of only by authorized personnel following radiation safety rules.

Typical Xofigo Treatment Schedule

Blood Tests Before Xofigo Doses

Blood count monitoring is a major part of Xofigo treatment. Xofigo can suppress bone marrow, which is where the body makes red blood cells, white blood cells, and platelets. Because of this, healthcare providers check blood tests before the first dose and before each later dose.

Before the first Xofigo dose, common minimum blood count requirements include:

• Absolute neutrophil count: at least 1.5 × 10⁹/L
• Platelet count: at least 100 × 10⁹/L
• Hemoglobin: at least 10 g/dL

Before later doses, the required blood counts may be lower but still must meet safety thresholds. If counts do not recover within the expected time, the healthcare team may delay or stop treatment. This is why Xofigo appointments often come with the glamorous accessory known as a lab draw.

Can the Xofigo Dose Be Adjusted?

Xofigo dosing is weight-based, so the calculated amount depends on the patient’s current body weight and the decay-corrected radioactivity concentration of the vial. There is no standard “lower tablet strength” or “split the dose in half” strategy like with many oral medicines.

If a patient’s blood counts are too low, side effects are concerning, or another cancer treatment conflicts with Xofigo, the care team may delay a dose, stop treatment, or reassess the plan. Patients should not attempt to change the schedule on their own. With radiopharmaceutical therapy, “I’ll just wing it” is not a medical strategy.

Older Adults

No dosage adjustment is generally considered necessary solely because a patient is older. However, many people receiving Xofigo are older adults and may have other medical conditions, prior chemotherapy, lower marrow reserve, or bone health concerns. These factors can influence monitoring and treatment decisions.

Kidney or Liver Problems

Radium-223 is not mainly metabolized by the liver, and urinary excretion is minimal. Dose adjustment is not generally needed for mild liver impairment or mild to moderate kidney impairment. However, data are limited for more severe impairment, so the treating physician must evaluate each case carefully.

What If You Miss a Xofigo Appointment?

If you miss a scheduled Xofigo injection, contact your oncology or nuclear medicine team as soon as possible. Because Xofigo is radioactive, appointments involve ordering, timing, handling, and safe preparation. This is not like rescheduling a haircut. The medication has a decay timeline, and the clinic may need to coordinate a new treatment date.

Do not try to “double up” at the next visit. Xofigo is given according to a planned schedule, and any changes should be made by the healthcare team.

Common Side Effects of Xofigo

The most common side effects reported with Xofigo include:

• Nausea
• Diarrhea
• Vomiting
• Peripheral edema, such as swelling in the legs, ankles, feet, or hands
• Low blood cell counts

Because nausea, vomiting, and diarrhea can lead to dehydration, patients are often encouraged to maintain good fluid intake unless their healthcare provider says otherwise. Signs such as dizziness, very dark urine, dry mouth, decreased urination, or feeling unusually weak should be reported promptly.

Serious Side Effects to Report

Call your healthcare provider right away if you notice symptoms such as unusual bruising or bleeding, fever, chills, signs of infection, shortness of breath, chest pain, severe weakness, black or bloody stools, or persistent vomiting or diarrhea. These symptoms may suggest low blood counts, infection, bleeding, dehydration, or other complications that need medical attention.

Important Drug Combination Warnings

Xofigo is not recommended for use in combination with abiraterone acetate plus prednisone or prednisolone outside of clinical trials. This warning is important because a clinical study found increased fractures and deaths in patients receiving that combination compared with patients receiving abiraterone and prednisone or prednisolone without Xofigo.

Concomitant chemotherapy with Xofigo is also generally not recommended outside a clinical trial because of the potential for added bone marrow suppression. Patients should give their care team a full list of all medications, supplements, cancer treatments, radiation treatments, and bone health medicines they are taking.

Radiation Safety After Xofigo

Although Xofigo’s alpha radiation has a short tissue range, patients still receive radiation safety instructions. Body fluids such as urine, stool, and vomit may contain radioactive material for a period after treatment. Your clinic may advise precautions such as sitting while urinating to reduce splashing, flushing the toilet several times, washing hands well, wearing gloves when handling soiled laundry or body fluids, and washing contaminated clothing separately.

These steps are not meant to make your home feel like a sci-fi containment zone. They are practical, temporary precautions designed to reduce exposure for caregivers, family members, and others.

How to Prepare for a Xofigo Injection

Preparation may vary by cancer center, but many patients can expect the following:

• Blood tests before treatment
• Review of current symptoms and side effects
• Medication list review
• Weight check for dose calculation
• Discussion of hydration and bowel symptoms
• Radiation safety instructions
• Scheduling of the next monthly injection

Bring your medication list, ask questions, and report changes such as new pain, recent infection, bleeding, major weight change, worsening diarrhea, or new treatment from another doctor. In cancer care, small details can matter. A new supplement may seem harmless, but your oncology team still needs to know about it.

Practical Experiences Related to Xofigo Dosage and Treatment

Patients and caregivers often describe Xofigo treatment as surprisingly quick on injection day, especially compared with long chemotherapy infusions. The actual IV injection may take only about a minute, but the full appointment can feel longer because of preparation, blood work, waiting, safety checks, and coordination with the nuclear medicine team. For many people, the rhythm becomes familiar: lab test, provider review, injection, instructions, then the next monthly appointment on the calendar.

One common experience is that the dose feels abstract. With many medications, patients can picture the amount: one tablet, two capsules, one teaspoon, or a patch. Xofigo dosage is different because it is calculated in radioactivity units based on body weight. A patient may hear “55 kBq per kilogram” and understandably think, “That sounds like something NASA should be handling.” The reassuring part is that patients do not need to calculate it themselves. The clinical team measures, verifies, and administers the dose using specialized procedures.

Another experience is the importance of blood counts. Some patients feel well but still need a delay because lab results are not ready for the next injection. This can be frustrating. From the patient’s perspective, it may feel like the body is saying “I’m fine,” while the lab report is waving a caution flag. The reason is that bone marrow suppression can be serious even before a person feels obvious symptoms. Regular monitoring helps reduce the risk of infection, bleeding, and anemia-related problems.

Digestive side effects are also commonly discussed. Nausea, diarrhea, or vomiting may be mild for some people and more bothersome for others. A practical strategy is to tell the care team early rather than waiting until dehydration becomes a bigger issue. Patients may be advised to drink fluids, track bowel movements, and report symptoms that are persistent or severe. Nobody wins a medal for silently enduring diarrhea. In oncology, communication is not complaining; it is useful data.

Radiation safety instructions can feel intimidating at first, especially for family members. The idea that body fluids may contain radioactive material sounds dramatic, but the daily precautions are usually simple: use the toilet carefully, flush as instructed, wash hands, handle soiled laundry with gloves, and follow the clinic’s written guidance. Many caregivers feel more comfortable once they understand that these precautions are temporary and practical rather than panic-worthy.

Patients may also experience emotional ups and downs during the six-dose schedule. A monthly treatment plan can feel manageable, but it also marks time in a very visible way. Some people feel encouraged by having an active treatment plan. Others feel anxious before each lab test or scan discussion. Both reactions are normal. Support from oncology nurses, social workers, family members, and patient groups can make the process less isolating.

Finally, Xofigo treatment often teaches patients to become organized. Keeping a folder or digital note with appointment dates, lab results, current medications, side effects, questions, and emergency phone numbers can be extremely helpful. Advanced cancer care is already complicated; a simple checklist can prevent the “I knew I meant to ask something” moment that reliably appears five minutes after leaving the clinic parking lot.

Conclusion

Xofigo dosage is precise, weight-based, and carefully controlled. The usual dose is 55 kBq per kilogram of body weight, given by slow IV injection once every 4 weeks for a total of 6 injections. It comes as a clear, colorless solution in a single-dose vial and is administered only by trained healthcare professionals in a clinical setting.

The most important things patients should understand are simple: keep every lab appointment, tell the care team about all medicines and side effects, follow radiation safety instructions, and never try to adjust the schedule on your own. Xofigo may sound complex because it involves radioactivity, decay correction, and specialized handling, but the patient-facing routine is usually straightforward: monthly treatment, regular blood tests, symptom monitoring, and close communication with the oncology team.